Menu

Blog

Jun 5, 2024

Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer

Posted by in category: biotech/medical

Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024.

Leave a reply